290 related articles for article (PubMed ID: 35594048)
1. Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Vannier AGL; Shay JES; Fomin V; Patel SJ; Schaefer E; Goodman RP; Luther J
JAMA Netw Open; 2022 May; 5(5):e2213014. PubMed ID: 35594048
[TBL] [Abstract][Full Text] [Related]
2. Psychotherapy for Alcohol Use Disorder Is Associated With Reduced Risk of Incident Alcohol-Associated Liver Disease.
Vannier AGL; Przybyszewski EM; Shay J; Patel SJ; Schaefer E; Goodman RP; Luther J
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1571-1580.e7. PubMed ID: 35964893
[TBL] [Abstract][Full Text] [Related]
3. Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis.
Alexandre W; Muhammad H; Agbalajobi O; Zhang G; Gmelin T; Adejumo A; Noll A; Jonassaint NL; DiMartini A; Bataller R; Rogal SS
BMC Gastroenterol; 2023 Feb; 23(1):29. PubMed ID: 36732709
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
6. Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.
Rogal S; Youk A; Zhang H; Gellad WF; Fine MJ; Good CB; Chartier M; DiMartini A; Morgan T; Bataller R; Kraemer KL
Hepatology; 2020 Jun; 71(6):2080-2092. PubMed ID: 31758811
[TBL] [Abstract][Full Text] [Related]
7. Disentangling the contributions of alcohol use disorder and alcohol-related liver disease towards dementia: A population-based cohort study.
Zhao S; Widman L; Hagström H; Shang Y
Addiction; 2024 Apr; 119(4):706-716. PubMed ID: 38044804
[TBL] [Abstract][Full Text] [Related]
8. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Burnette EM; Nieto SJ; Grodin EN; Meredith LR; Hurley B; Miotto K; Gillis AJ; Ray LA
Drugs; 2022 Feb; 82(3):251-274. PubMed ID: 35133639
[TBL] [Abstract][Full Text] [Related]
9. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Castrén S; Mäkelä N; Alho H
Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
[TBL] [Abstract][Full Text] [Related]
10. Moderate-high intensity exercise associates with reduced incident alcohol-associated liver disease in high-risk patients.
Shay JES; Vannier A; Tsai S; Mahle R; Diaz PM; Przybyszewski E; Challa PK; Patel SJ; Suzuki J; Schaefer E; Goodman RP; Luther J
Alcohol Alcohol; 2023 Sep; 58(5):472-477. PubMed ID: 37565935
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
[TBL] [Abstract][Full Text] [Related]
12. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
14. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV.
Frost MC; Matson TE; Tsui JI; Williams EC
Drug Alcohol Depend; 2019 Jan; 194():288-295. PubMed ID: 30469100
[TBL] [Abstract][Full Text] [Related]
15. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care.
Bernstein E; Guo N; Goto T; Rothberg MB
J Gen Intern Med; 2021 Jul; 36(7):1989-1996. PubMed ID: 33515195
[TBL] [Abstract][Full Text] [Related]
17. Association Between Alcohol Use Disorders and Outcomes of Patients Hospitalized With Community-Acquired Pneumonia.
Gupta NM; Lindenauer PK; Yu PC; Imrey PB; Haessler S; Deshpande A; Higgins TL; Rothberg MB
JAMA Netw Open; 2019 Jun; 2(6):e195172. PubMed ID: 31173120
[TBL] [Abstract][Full Text] [Related]
18. Repurposing drugs for treatment of alcohol use disorder.
Aubin HJ
Int Rev Neurobiol; 2024; 175():153-185. PubMed ID: 38555115
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians.
Shroff H; Gallagher H
Clin Ther; 2023 Dec; 45(12):1177-1188. PubMed ID: 37813775
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for alcohol use disorders - Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden.
Wallhed Finn S; Lundin A; Sjöqvist H; Danielsson AK
Drug Alcohol Depend; 2021 Oct; 227():108964. PubMed ID: 34518028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
